Table 2.
Diagnosis and treatment characteristics at baseline (n = 330) stratified by treatment type
Total (n = 330) | Locoregional treatment (n = 100) | Chemotherapy (n = 194) | Other systemic therapy (n = 30) | |
---|---|---|---|---|
Tumor diagnosis, n (%) | ||||
Breast cancer | 156 (47.3) | 23 (23.0) | 115 (59.3) | 17 (56.7) |
Male reproductive cancers | 34 (10.3) | 18 (18.0) | 6 (3.1) | 9 (30.0) |
Hematologic cancer | 30 (9.1) | 1 (1.0) | 25 (12.9) | 1 (3.3) |
Gastrointestinal cancer | 26 (7.9) | 8 (8.0) | 16 (8.2) | 1 (3.3) |
Colon cancer | 23 (7.0) | 9 (9.0) | 14 (7.2) | |
Skin cancer | 13 (3.9) | 13 (13.0) | ||
Gynecological cancer | 11 (3.3) | 4 (4.0) | 7 (3.6) | |
Head and neck cancer | 10 (3.0) | 8 (8.0) | 1 (0.5) | 1 (3.3) |
Lung cancer | 10 (3.0) | 1 (1.0) | 8 (4.1) | 1 (3.3) |
Urological cancer | 10 (3.0) | 10 (10.0) | ||
Endocrine cancer | 3 (0.9) | 3 (3.0) | ||
Bone cartilage and soft tissue cancer | 2 (0.6) | 1 (1.0) | 1 (0.5) | |
Central nervous system cancer | 1 (0.3) | 1 (0.5) | ||
Eye cancer | 1 (0.3) | 1 (1.0) | ||
Extent of disease, n (%) | ||||
Local | 109 (33.0) | 48 (48.0) | 49 (25.3) | 12 (40.0) |
Reginal | 93 (28.2) | 14 (14.0) | 75 (38.7) | 4 (13.3) |
Distant | 10 (3.0) | 7 (3.6) | 3 (10.0) | |
Unknown | 118 (35.8) | 38 (38.0) | 63 (32.5) | 11 (36.7) |
Treatment completed, n (%) | ||||
Yes | 208 (63.2) | 94 (94.9) | 104 (53.6) | 7 (23.3) |
No | 121 (36.8) | 5 (5.1) | 90 (46.4) | 23 (76.7) |
Time diagnosis to RTW, a M ± SD | 7.4 ± 6.4 | 5.6 ± 7.4 | 8.6 ± 5.5 | 4.5 ± 5.4 |
Memory symptoms,1 M ± SD | 32.1 ± 19.6 | 32.6 ± 18.9 | 31.7 ± 20.1 | 35.9 ± 18.7 |
Executive function symptoms,2 M ± SD | 19.3 ± 15.9 | 20.4 ± 14.9 | 18.0 ± 16.0 | 24.8 ± 17.5 |
Depressive symptoms, M ± SD | 4.6 ± 3.6 | 5.0 ± 3.9 | 4.3 ± 3.3 | 5.3 ± 4.1 |
Fatigue, M ± SD | 30.1 ± 11.4 | 30.6 ± 11.7 | 29.3 ± 11.2 | 33.6 ± 10.7 |
Note: M, mean; SD, standard deviation;. 1For the comparison between treatment types p = 0.564; 2 For the comparison between treatment types p = 0.083